GnRH agonist peptide analog
Goserelin
Goserelin is a synthetic GnRH analog investigated in pituitary responses and communication between cellular pathways. The molecule, acetate salt and preparation used in each publication must remain distinct.
This is a research reference, not a product offered in the Asciende catalog. Published studies do not establish the identity, purity or availability of a commercial preparation.
Hormonal axis, time and response type
Record time and model as well as name. A class label alone does not predict every response of a feedback system.
- Is the entity described as an agonist, antagonist or modulator in the cited assay?
- Are immediate response and adaptation after a different exposure distinguished?
- Is the biomarker a direct receptor readout or a consequence of the whole axis?
Mechanism described in the literature
Preclinical literature classifies goserelin as a GnRH agonist. Prostate models also examined a relationship between GnRH signaling and EGFR; this does not make goserelin a universal direct EGFR inhibitor.
Other names in the literature
- Goserelin
Responses during and after exposure
A 1988 work compared GnRH analogs, including goserelin according to article indexing, in rat pituitary research. It distinguished LH released during exposure, persistence afterward and tissue reserves, different aspects of the endocrine response.
A mutation as a mechanistic test
In 2002, investigators compared DU-145 cells with two EGFR versions and mouse xenografts. Goserelin acetate limited growth in the model with unmodified receptor, while the altered variant resisted that effect.
What a genetic control adds
The receptor comparison supported a cellular communication pathway in that experiment, more specifically than growth change alone. It does not demonstrate the same response in every GnRH-receptor-bearing cell or identify direct goserelin binding to EGFR.
Questions and answers
Does goserelin act directly on EGFR?
The cited study examined pathway communication in preclinical models; it did not establish direct binding to EGFR.
Why also measure pituitary reserves?
Tissue content and released hormone are different variables, examined separately in the analog comparison.
Sources
- Commercially available analogues of GnRH and LH secretion. — Acta Endocrinol (Copenh), 1988
- Commercially available analogues of GnRH and LH secretion.
- Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling. — Clin Cancer Res, 2002